Nutritional and Metabolic Diseases

441 trials 157 recruiting

Filter these 441 trials by phase, country and sponsor.

Open in Search →

A study to test whether BI 456906 helps people living with overweight or obesity who do not have diabetes to lose weight Ended

2022-502529-17-00 Obesity 5 2024-01-18
A study to test whether BI 456906 helps people living with overweight or obesity who also have diabetes to lose weight Ended

2022-502531-18-00 Obesity 5 2024-01-18
Effect of orlistat on LIVER fat content in obese subjects with NAFLD and High concEntrAtion of pLasma proneurotensin THrough inhibition of n… Ended

2022-500366-10-00 Non-Alcoholic Fatty Liver Disease 4 2024-01-09
A research study to see how a new weekly insulin, insulin icodec when given along with semaglutide helps in reducing the blood sugar level i… Ended

2022-502717-28-00 Diabetes Type 2 5 2024-01-09
Effects of extensive Weight loss on Insulin resistance and Lipid-kinetics in people with obesity and fatty liver Disease Ended

2023-506300-12-00 Obesity, Non-alcoholic Fatty Liver Disease 6 2023-12-18
A study in women with overweight or obesity to test whether different doses of BI 456906 influence the amount of a contraceptive in the bloo… Ended

2022-503146-53-00 pharmacokinetic trial 3 2023-12-07
Functional Constipation: A Phase 2 Dose Finding Study Evaluating the Safety and Efficacy of Linaclotide in Pediatric Subjects 6 Months to Le… Ended

2022-501947-34-00 Functional Constipation (FC) 4 2023-12-05
A study to assess the pharmacokinetics, and glucodynamics of LY3209590 in participants with type 2 diabetes Ended

2023-508008-39-00 Type 2 Diabetes Mellitus 3 2023-12-05
An open label, balanced, randomized, single dose, two treatment, two period, two sequence, crossover, bioequivalence study comparing Dapagli… Ended

2023-506408-18-00 diabetes 2 2023-11-21
A randomised, placebo-controlled, double-blinded, cross-over, Phase 1 study evaluating the safety and preliminary efficacy of the GLP 1 anal… Ended

2023-507758-34-00 Overweight 3 2023-11-10
Exploratory Bioavailability of Two Formulations of Gliclazide MR Tablets 120 mg (I.R.I.S.) in Healthy Volunteers Under Fed and Fasting Condi… Ended

2023-507802-15-00 Type 2 diabetes mellitus 3 2023-11-07
REIMAGINE 2: A research study to see how well CagriSema compared to semaglutide, cagrilintide and placebo lowers blood sugar and body weight… Ended

2022-502678-18-00 Type 2 diabetes 5 2023-11-07
Randomised, crossover bioequivalence clinical trial of linagliptin 5 mg film-coated tablets, after a single oral dose administration to heal… Ended

2023-506047-41-00 diabetes 2 2023-11-07
An open label, randomized, four-period, four-sequence single dose, crossover trial in healthy volunteers to determine the relative bioavaila… Ended

2022-502420-51-00 No therapeutic indication in the current trial with hea 2 2023-10-23
A Study of LY3437943 in Participants Who Have Obesity or Overweight (TRIUMPH-1) Ended

2023-503657-35-00 Obesity 5 2023-10-10
Investigation of safety, tolerability and pharmacokinetics of multiple doses of NNC0113‑6856 in healthy participants, including a subset of … Ended

2023-503891-26-00 Type 2 diabetes 3 2023-09-29
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight and Type 2 Diabetes (ATTAIN-2) Ended

2022-502837-24-00 Overweight 5 2023-09-25
Control Of BioEquivalence with Xenical (COBEX): A Phase I, randomized, active-control study to evaluate EMP22 pharmacodynamics and EMP16 pha… Ended

2023-505671-74-00 Obesity 2 2023-09-22
A Ph3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects with Severe Hypertriglyceridemia: The ENTRUST study Ended

2023-503576-25-00 Severe Hypertriglyceridemia 5 2023-09-22
A study to compare how different medicines (rosuvastatin, digoxin, metformin, and furosemide) are handled by the body of healthy people and … Ended

2024-514621-29-00 1. Patients with compensated liver cirrhosis due to any 3 2023-09-07
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3) Ended

2023-503659-88-00 Obesity 5 2023-09-05
A Phase 2b Study of MK-6024 in Adults with Precirrhotic Nonalcoholic Steatohepatitis Ended

2022-502647-35-00 Non-alcoholic steatohepatitis 4 2023-09-01
A Study of LY3437943 in Participants with Type 2 Diabetes Mellitus who have Obesity or Overweight (TRIUMPH-2) Ended

2023-503658-11-00 Type 2 Diabetes 5 2023-08-31
FXR Effect on Severe Alcohol-Associated Hepatitis (FRESH) Study Ended

2024-512913-42-00 Severe Alcohol-Associated Hepatitis 4 2023-08-21